NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIAL

The paper contains а results of the study of the pharmacokinetics, tolerability and safety of a new influenza drug Triazide in several dose regimens conducted on healthy volunteers. The convenient method for the determining the Triazide in blood plasma and urine by the HPLC have been proposed for th...

Full description

Bibliographic Details
Main Authors:	E. G. Deyeva, Yu. I. Shevchik, A. A. Shaldghan, K. A. Zagorodnikova, A. A. Tumashov, A. V. Baklykov, S. K. Kotovskaya, O. N. Chupahin, V. N. Charushin, V. L. Rusinov, D. S. Kopchuk
Format:	Article
Language:	Russian
Published:	LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2019-01-01
Series:	Разработка и регистрация лекарственных средств
Subjects:	triazide influenza clinical research safety pharmacokinetics
Online Access:	https://www.pharmjournal.ru/jour/article/view/623

id	doaj-40894e12a0b44763b2c48a47d8af313f
record_format	Article
spelling	doaj-40894e12a0b44763b2c48a47d8af313f2021-07-28T13:06:56ZrusLLC Center of Pharmaceutical Analytics (LLC «CPHA»)Разработка и регистрация лекарственных средств2305-20662658-50492019-01-0103172180623NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIALE. G. Deyeva0Yu. I. Shevchik1A. A. Shaldghan2K. A. Zagorodnikova3A. A. Tumashov4A. V. Baklykov5S. K. Kotovskaya6O. N. Chupahin7V. N. Charushin8V. L. Rusinov9D. S. Kopchuk10Research Institute of Influenza of Ministry of healthcare of the Russian FederationResearch Institute of Influenza of Ministry of healthcare of the Russian FederationResearch Institute of Influenza of Ministry of healthcare of the Russian FederationNorth-Western State Medical University named after I. I. MechnikovI. Ya. Postovsky Institute of organic synthesis of UB of RASI. Ya. Postovsky Institute of organic synthesis of UB of RAS; Ural Federal University named after the first President of Russia B. N. YeltsinI. Ya. Postovsky Institute of organic synthesis of UB of RAS; Ural Federal University named after the first President of Russia B. N. YeltsinI. Ya. Postovsky Institute of organic synthesis of UB of RAS; Ural Federal University named after the first President of Russia B. N. YeltsinI. Ya. Postovsky Institute of organic synthesis of UB of RAS; Ural Federal University named after the first President of Russia B. N. YeltsinI. Ya. Postovsky Institute of organic synthesis of UB of RAS; Ural Federal University named after the first President of Russia B. N. YeltsinI. Ya. Postovsky Institute of organic synthesis of UB of RAS; Ural Federal University named after the first President of Russia B. N. YeltsinThe paper contains а results of the study of the pharmacokinetics, tolerability and safety of a new influenza drug Triazide in several dose regimens conducted on healthy volunteers. The convenient method for the determining the Triazide in blood plasma and urine by the HPLC have been proposed for the using in this study. There was no reliable statistical relationship between drug intake, undesirable clinical events and changes in laboratory parameters. A study of the pharmacokinetics have been showed that Triazide in the blood plasma was found on average after 0.5 hours, the curve of decrease in concentrations was two-phase, the half-life in the first phase was 1.5-4.0 hours. The maximum concentrations with increasing dose increased in direct proportion. With an increase in the daily dose, the maximum concentration was reached earlier. At the same time, no significant cumulation was observed with prolonged use. In the study, Triazide was well tolerated by all participants in all studied dose regimens. Preferred regimens that provide maintenance of effective and safe concentrations, appearances were 300 mg two and three times a day.https://www.pharmjournal.ru/jour/article/view/623triazideinfluenzaclinical researchsafetypharmacokinetics
collection	DOAJ
language	Russian
format	Article
sources	DOAJ
author	E. G. Deyeva Yu. I. Shevchik A. A. Shaldghan K. A. Zagorodnikova A. A. Tumashov A. V. Baklykov S. K. Kotovskaya O. N. Chupahin V. N. Charushin V. L. Rusinov D. S. Kopchuk
spellingShingle	E. G. Deyeva Yu. I. Shevchik A. A. Shaldghan K. A. Zagorodnikova A. A. Tumashov A. V. Baklykov S. K. Kotovskaya O. N. Chupahin V. N. Charushin V. L. Rusinov D. S. Kopchuk NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIAL Разработка и регистрация лекарственных средств triazide influenza clinical research safety pharmacokinetics
author_facet	E. G. Deyeva Yu. I. Shevchik A. A. Shaldghan K. A. Zagorodnikova A. A. Tumashov A. V. Baklykov S. K. Kotovskaya O. N. Chupahin V. N. Charushin V. L. Rusinov D. S. Kopchuk
author_sort	E. G. Deyeva
title	NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIAL
title_short	NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIAL
title_full	NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIAL
title_fullStr	NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIAL
title_full_unstemmed	NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIAL
title_sort	new antiviral drug triazid. results of first phase of clinical trial
publisher	LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
series	Разработка и регистрация лекарственных средств
issn	2305-2066 2658-5049
publishDate	2019-01-01
description	The paper contains а results of the study of the pharmacokinetics, tolerability and safety of a new influenza drug Triazide in several dose regimens conducted on healthy volunteers. The convenient method for the determining the Triazide in blood plasma and urine by the HPLC have been proposed for the using in this study. There was no reliable statistical relationship between drug intake, undesirable clinical events and changes in laboratory parameters. A study of the pharmacokinetics have been showed that Triazide in the blood plasma was found on average after 0.5 hours, the curve of decrease in concentrations was two-phase, the half-life in the first phase was 1.5-4.0 hours. The maximum concentrations with increasing dose increased in direct proportion. With an increase in the daily dose, the maximum concentration was reached earlier. At the same time, no significant cumulation was observed with prolonged use. In the study, Triazide was well tolerated by all participants in all studied dose regimens. Preferred regimens that provide maintenance of effective and safe concentrations, appearances were 300 mg two and three times a day.
topic	triazide influenza clinical research safety pharmacokinetics
url	https://www.pharmjournal.ru/jour/article/view/623
work_keys_str_mv	AT egdeyeva newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT yuishevchik newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT aashaldghan newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT kazagorodnikova newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT aatumashov newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT avbaklykov newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT skkotovskaya newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT onchupahin newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT vncharushin newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT vlrusinov newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial AT dskopchuk newantiviraldrugtriazidresultsoffirstphaseofclinicaltrial
_version_	1721276718077968384

NEW ANTIVIRAL DRUG TRIAZID. RESULTS OF FIRST PHASE OF CLINICAL TRIAL

Similar Items